Endogenous androgen levels in epithelium and stroma of human benign prostatic hyperplasia and normal prostate

Bartsch, W.; Krieg, Michael; Becker, H.; Mohrmann, J.; Voigt, Kai‐Ingo

doi:10.1530/acta.0.1000634

Cited by 29 publications

(19 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, since from microscopy (Bolton et al 1981) it is apparent that the relative volumes of epithelial and stromal cells are considerably larger than those of their nuclei, the results indicate that at least these three androgens are much more concentrated in the nucleus than in the cytoplasm. These results are in agreement with those of Bartsch, Krieg, Becker, Mohrmann & Voigt (1982), who reported that in human BPH, 5a-dihydrotestosterone is mainly located in the nuclear fraction, there being significantly greater concentrations in stromal than in epithelial nuclei. They also reported that the concentrations of 5a-androstane3a,17ß-diol in human BPH nuclei were undetectable.…”

Section: Discussionsupporting

confidence: 93%

Androgen concentrations in epithelial and stromal cell nuclei of human benign prostatic hypertrophic tissues

Lahtonen¹,

Bolton²,

Lukkarinen³

et al. 1983

Journal of Endocrinology

View full text Add to dashboard Cite

Prostate tissues removed from patients with benign prostatic hypertrophy were separated into epithelial and stromal components and nuclei purified from these. The concentrations of testosterone, 5 alpha-dihydrotestosterone, 5 alpha-androstane-3 alpha,17 beta-diol, 4-androstene-3,17-dione, 5 alpha-androstanedione and androsterone in pooled preparations of the purified nuclei were determined by radioimmunoassays after the purification of solvent steroid extracts by Lipidex-5000 column chromatography. The most abundant androgen measured was 5 alpha-dihydrotestosterone and it was significantly (P less than 0.05) more concentrated in the stromal nuclei than in the epithelial nuclei. The mean concentration of androsterone was also significantly (P less than 0.05) greater in the stromal nuclei whereas that of testosterone was equal in the two nuclear types. The concentrations of 5 alpha-androstane-3 alpha,17 beta-diol, 4-androstene-3,17-dione and 5 alpha-androstanedione were below the sensitivity limits of the assays in the majority of cases, but the results indicated that when detectable the first two were more concentrated in the stromal than the epithelial nuclei. The results emphasize the importance of the prostatic stroma in androgen metabolism, and the relative concentrations of 5 alpha-dihydrotestosterone and testosterone indicated identical 5 alpha-reductase activities in the nuclei in comparison with respective whole cell epithelial and stromal preparations. 5 alpha-Dihydrotestosterone concentrations were clearly higher than the nuclear androgen receptor levels previously reported from this laboratory.

show abstract

Section: Discussionsupporting

confidence: 93%

Androgen concentrations in epithelial and stromal cell nuclei of human benign prostatic hypertrophic tissues

Lahtonen¹,

Bolton²,

Lukkarinen³

et al. 1983

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Protein was measured by the biuret reaction and DNA by the modified Burton method as reported earlier (Bartsch et al 1982(Bartsch et al , 1983. The protein content of the cytosol was found in the range of 14-22 mg/ml.…”

Section: Miscellaneousmentioning

confidence: 94%

“…Before discussing androgen and androgen re¬ ceptor concentrations in the subcellular fractions of the prostate, several methodological problems should be mentioned which lead to differences in the in vitro as compared to the in vivo situation; these have been previously discussed in detail. 1) During fractionation, the tissue redistribution of androgens (Bartsch et al 1980(Bartsch et al , 1982 and of androgen receptors (Martin & Sheridan 1982) can¬ not be avoided. The order of magnitude of such processes is unknown; however, it seems probably that protein and steroid not retained tightly by the nuclei might be preferentially released from this compartment during tissue homogenisation and purification.…”

Section: Cyacmentioning

confidence: 99%

Interactions of an anti-androgen (cyproterone acetate) with the androgen receptor system and its biological action in the rat ventral prostate

Huang¹,

Bartsch²,

Voigt³

1985

Acta Endocrinologica

Self Cite

View full text Add to dashboard Cite

Male Wistar rats were castrated and implantated with testosterone-filled silastic depots (in vitro release rate: 60 \g=m\g/24h) prior to treatment with 10 mg cyproterone acetate (CyAc) on day 1, and 5 mg on days 4, 7, 10 and 13. Animals were sacrificed on day 14. Control animals were treated identically, with the exception of CyAc administration. Blood was collected and the ventral prostates of 6\p=n-\8 animals were pooled, homogenized and processed into cytosol and purified nuclei. Steroid determinations (CyAc, testosterone, 5\g=a\-dihydrotestosterone (DHT), 5\g=a\-androstane-3\g=a\,17\g=b\-diol(3\g=a\-diol))were performed by RIA. Specifically bound DHT (charcoal resistant DHT = CR-DHT) represents DHT values (RIA) following treatment of cytosol or nuclear extract with dextran coated charcoal. The androgen receptor was determined in cytosol and nuclear extract by 'exchange assay' using [3H]methyltrienolone (MT) (18 h, 15\ s=deg\ C).The main results were: 1) The steroid levels in plasma (testosterone, DHT, 3\g=a\-diol) were in the range of untreated adult animals and not significantly influenced by the CyAc treatment. Final CyAc levels were 305 \m=+-\58 nmol/l (mean \ m=+-\SD, n = 5). 2) Significantly lower DHT, CR-DHT and testosterone levels (P at least < 0.01) were found in cytosol and in nuclei in the CyAc-treated group (cytosol (fmol/mg protein): DHT 305 \ m=+-\ 61 (n = 5), CR-DHT 54 \ m=+-\ 37 (n = 8), testosterone \ m=l e\ 8 (n = 5); nuclei (pmol/mg DNA): DHT 0.4 \ m=+-\0.2 (n = 5), CR\ x=req-\ DHT 0.7 \ m=+-\0.2 (n = 3), testosterone \m=l e\ 0.2 (n = 5)) when compared to controls (cytosol: DHT 645 \ m=+-\ 232 (n = 15), CR-DHT 204 \ m=+-\49 (n = 8), testosterone 24 \m=+-\12 (n = 10); nuclei: DHT 5.0 \ m=+-\2.5 (n = 12), CR-DHT 3.1 \m=+-\0.7 (n = 5), testosterone 0.9 \m=+-\0.6 (n = 7)). 3\g=a\-diol was similar in the cytosol of both groups and could not be detected in the nuclei. 3) The androgen receptor concentration was increased in the cytosol of the CyAc-treated group (216 \ m=+-\17 (n = 4), control group 98 \ m=+-\ 10 (n = 5) fmol/mg protein, P < 0.001)) and decreased in the nuclear extract (0.61 \m=+-\0.25 (n = 4), control 1.75 \ m=+-\0.25 (n = 5) pmol/mg DNA, P < 0.001). 4) The weight and DNA content of the prostate were reduced following CyAc treatment (weight 191 \m=+-\11 mg (n = 9), DNA 622 \m=+-\61 \g=m\g/organ(n = 8), controls 312 \m=+-\9 (n = 8) and 838 \m=+-\103 (n = 8), respectively). The data demonstrate that an approximate 40-fold excess of CyAc over testosterone in plasma led to a distinct but partial reduction of nuclear DHT and androgen receptor values coinciding with partial effects on prostate weight and DNA content. These results reflect the ability of the prostate to maintain significant androgen stimulation in the presence of low nuclear DHT and androgen receptor values.

show abstract

“…[21] Although the reports regarding higher intraprostatic levels of DHT are paradoxical, there is strong evidence to suggest the central role of DHT in the development and progression of BPH. [22,23] …”

Section: Role Of Androgens In Bphmentioning

confidence: 99%

Current status of 5α-reductase inhibitors in the treatment of benign hyperplasia of prostate

Kumar¹,

Wahane²

2008

Indian J Med Sci

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) is a common problem in aging menof BPH include increased urinary frequency, urgency, intermittency; nocturia; decreased force of stream; hesitancy and straining that are usually associated with complications such as acute urinary retention, urinary incontinence, recurrent urinary tract infection, hematuria, renal failure, and bladder stone. [4][5][6][7][8][9] The primary goal for treating symptomatic BPH is to improve urine ß ow, for which both surgical and nonsurgical approaches are available. Surgical treatment for BPH is usually indicated in recurrent cases of urinary retention, urinary tract infections, hematuria, and in azotemia.

show abstract

Endogenous androgen levels in epithelium and stroma of human benign prostatic hyperplasia and normal prostate

Cited by 29 publications

References 21 publications

Androgen concentrations in epithelial and stromal cell nuclei of human benign prostatic hypertrophic tissues

Androgen concentrations in epithelial and stromal cell nuclei of human benign prostatic hypertrophic tissues

Interactions of an anti-androgen (cyproterone acetate) with the androgen receptor system and its biological action in the rat ventral prostate

Current status of 5α-reductase inhibitors in the treatment of benign hyperplasia of prostate

Contact Info

Product

Resources

About